前列腺穿刺活检前使用MRI进行风险分层的真实世界应用
该回顾性单中心研究纳入2018至2021年2900例PSA升高(2-20 ng/mL)男性,分析活检前MRI使用趋势及结局。MRI使用率从2018年56%升至2021年89%(p<0.001),使31%男性避免活检,临床显著前列腺癌检出提高13%,Gleason分级组1疾病减少3%,阴性活检减少10%(p<0.001)。黑种人和医疗补助保险与MRI使用减少相关。
要点
- 活检前MRI使用率从2018年56%升至2021年89%(p<0.001)。
- MRI使31%男性避免活检,临床显著前列腺癌检出提高13%。
- 黑种人和医疗补助保险与MRI使用减少相关(均p<0.001)。
核心结论
- 在这4年研究期间,MRI作为PSA升高的风险分层工具使用率上升,但黑种人和医疗补助保险覆盖者MRI使用率较低,且观察到显著的提供者层面变异,作者认为需进一步研究以明确影响MRI作为常规风险评估工具实施的因素。
研究设计与样本
- 回顾性单中心研究,纳入2018年至2021年2900例PSA升高(2-20 ng/mL)的男性,分析MRI使用趋势及按MRI使用情况分组的前列腺活检结局,并采用单因素和多因素逻辑回归计算比值比以识别患者和提供者层面MRI使用的预测因素。
主要发现
- 活检前MRI使用率从2018年56%上升至2021年89%(p<0.001)。
- 活检前MRI使31%的男性避免活检。
- MRI使用使临床显著前列腺癌检出提高13%,使Gleason分级组1疾病识别减少3%,使阴性活检减少10%(p<0.001)。
- 接受MRI的男性更可能年龄小于75岁、拥有私人保险或Medicare保险、PSA>4 ng/mL以及PHI>27。
- 在单因素和多因素分析中,黑种人和医疗补助保险均与MRI使用减少相关(均p<0.001),泌尿科提供者是MRI使用的独立预测因素(p<0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The utilization of MRI to risk stratify elevated PSA prior to prostate biopsy has been inconsistently adopted and varies considerably by practice setting. This study aims to evaluate the usage and performance of MRI as an advanced risk stratification tool of elevated PSA prior to biopsy and identify factors associated with differential utilization of MRI at a large academic setting with ready access to 3T multiparametric MRI of the prostate. METHODS: A retrospective single-center study of 2900 men presenting with elevated PSA 2-20 ng/mL from 2018 through 2021 was conducted. We analyzed trends in MRI utilization and outcomes of prostate biopsy by MRI usage. Univariate and multivariate logistic regressions were performed to calculate odds ratios to identify patient- and provider-level predictors of MRI usage. RESULTS: Rates of prebiopsy MRI utilization increased from 56% in 2018 to 89% in 2021 (p < 0.001). Prebiopsy MRI led to biopsy avoidance in 31% of men. MRI usage enhanced detection of clinically significant prostate cancer by 13% and reduced identification of Gleason Grade Group 1 disease by 3% and negative biopsies by 10% (p < 0.001). Men who received MRI were more likely to be younger than 75 years in age and have private or Medicare insurance, PSA >4 ng/mL, and PHI >27. In both univariate and multivariate analysis, black race and Medicaid insurance were associated with reduced MRI utilization (all p < 0.001). Urologic provider was an independent predictor of MRI usage (p < 0.001). CONCLUSIONS: Use of MRI as a risk stratification tool for elevated PSA rose during this 4-year study period. Men who self-identify as black or men with Medicaid coverage have diminished rates of MRI usage. Considerable provider-level variability in MRI use was observed. Future research aimed at identifying factors affecting implementation of MRI as a routine risk assessment tool is warranted.
引用
- Siddiqui MR, Ansbro B, Shah PV, et al. Real-world use of MRI for risk stratification prior to prostate biopsy. Prostate Cancer Prostatic Dis. 2022. PMID: 35551235. doi:10.1038/s41391-022-00543-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。